Site article, page-8

I wouldn't completely discount Behrenbruch, he is certainly opiniated and I feel he hasn't done full research into eg ADO, but his biog shows he knows a thing or two about the biotech environment..................


"Dr. Behrenbruch received a degree in electrical engineering and computer science from Monash University and received a D.Phil (Ph.D) in biomedical engineering from Oxford University in Sir Prof. Mike Brady’s “Medical Vision Laboratory” in the field of imaging and diagnosis of breast cancer. He also took additional graduate study in computational biology and genomics at Stanford University. He holds a Master of Business Administration (MBA) jointly awarded from New York University and the London School of Economics (TRIUM program) and has a strong background in corporate finance and negotiation. Dr. Behrenbruch holds over 60 peer-reviewed publications and patents in the field of medical informatics, biotechnology and nanotechnology.

A serial entrepreneur, Dr. Behrenbruch started his career with BHP Asia (Vietnam) in the oil and gas industry and Siemens Telecommunications (Asia/Pacific). In the late 90’s, he was involved instarting several UK-based companies including Oxford Medical Image Analysis and Mirada Solutions. In 2003 during his term as CEO, Mirada Solutions was sold to CTI Molecular Imaging (NASDAQ: CTMI) and he became President of the IT and bioinformatics division of CTI as well as Managing Director of CTI’s European operations. In 2005, CTI became part of Siemens Medical Solutions in a $1.1B acquisition and Dr. Behrenbruch was a Vice President at Siemens during the 18-month post-merger integration, with a focus on clinical applications and product marketing. His responsibilities at Siemens included luminary customer relationships and key corporate-level interfacing projects such as GlaxoSmithKline’s Hammersmith imaging centre and Singapore’s “Biopolis”.

From 2007–9, Dr. Behrenbruch was a Professor in the Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, at the University of California, Los Angeles (UCLA). His appointment at UCLA followed a successful track record in commercializing biotechnology, healthcare IT and medical devices. His laboratory focused on the technical and clinical challenges of introducing new device, instrumentation and nanotechnology solutions into the healthcare practice and he continues to teach in the area of life sciences commercialization and technology transfer. Dr. Behrenbruch was also a visiting academic at the Zhejiang-California Nanosystems Institute, Zhejiang University in Hangzhou, China (2006-2009) and has taught entrepreneurship classes at UCLA (David Geffen School of Medicine, Henry Samueli School of Engineering and Applied Science and Anderson School of Business), Oxford University (Saïd Business School), California Institute of Technology (Caltech), ESMT (Berlin), Zhejiang University (China) and the University of Sydney. He was formerly a UC Discovery Mentor (Univ. of California’s entrepreneurship program) and is a regular reviewer for US National Institutes of Health / National Science Foundationgrants and several leading science and medical journals.